REHOVOT, Israel, Jan. 6, 2020 /PRNewswire/ -- CollPlant
(NASDAQ:CLGN), a regenerative medicine company, today announced it
is now part of a new public-private ManufacturingUSA initiative,
the Advanced Regenerative Manufacturing Institute (ARMI).
Headquartered in Manchester, New
Hampshire, ARMI brings together a consortium of over 150
partner organizations from industry, government, academia and the
non-profit sector to develop next-generation manufacturing
processes and technologies for cells, tissues and organs.
Approximately $80 million from the
US federal government is combined with more than $200 million in cost share to support the
development of tissue and organ manufacturing capabilities. ARMI
leads the Advanced Tissue Biofabrication Manufacturing Institute on
behalf of the US Department of Defense. ARMI works to integrate and
organize the fragmented collection of industry practices and
domestic capabilities in tissue Biofabrication technology to better
position the US relative to global competition. ARMI focuses on
accelerating regenerative tissue research and creating
state-of-the-art manufacturing innovations in biomaterial and cell
processing for critical Department of Defense and civilian needs.
ARMI's efforts are supported by industrial partners, academic and
academically affiliated partners, and government and nonprofit
partners. The ARMI partnership continues to grow.
ARMI's Chairman, inventor Dean
Kamen stated, "We need to develop 21st century tools for
engineered tissue manufacturing that will allow these innovations
to be widely available – similar to how a 15th century tool (the
printing press) allowed knowledge to spread widely during the
Renaissance. As an ever-growing ecosystem of industrial,
governmental, academic, non-profit and clinical institutions, I
have no doubt that we can achieve our mission to make
practical the large-scale manufacturing of engineered tissues
and tissue-related technologies, to benefit existing industries and
grow new ones."
Yehiel Tal, CollPlant's Chief
Executive Officer commented, "CollPlant is very pleased to enter
into this collaboration with ARMI and its network of partners from
industry, academia, and the U.S. federal government. We all share
the common goal of advancing 3D bioprinting and next-generation
manufacturing of tissues and organs. We believe CollPlant's
BioInks, based on our rhCollagen, are the ideal building block for
tissue and organ manufacturing, and we are proud to contribute our
expertise and to advance the entire science and industry of
bioengineering and manufacturing. CollPlant is honored to be a part
of this network of industry leaders."
About ARMI
The Advanced Regenerative Manufacturing Institute (ARMI),
headquartered in Manchester, NH,
is a ManufacturingUSA Institute. It brings together a
consortium of over 150 partners from across industry, government,
academia and the non-profit sector to develop next-generation
manufacturing processes and technologies for cells, tissues and
organs. ARMI will work to organize the current fragmented domestic
capabilities in tissue Biofabrication technology to better position
the U.S. relative to global competition. For more information on
ARMI, please visit www.armiusa.org.
About CollPlant
CollPlant is a regenerative medicine company focused on 3D
bioprinting of tissues and organs, and medical aesthetics. Our
products are based on our rhCollagen (recombinant human collagen)
that is produced with CollPlant's proprietary plant based genetic
engineering technology.
Our products address indications for the diverse fields of organ
and tissue repair, and are ushering in a new era in regenerative
medicine. Our flagship rhCollagen BioInk product line is ideal for
3D bioprinting of tissues and organs. In October 2018, we entered into a licensing
agreement with United Therapeutics, whereby United Therapeutics is
using CollPlant's BioInks in the manufacture of 3D bioprinted lungs
for transplant in humans.
For more information about CollPlant, visit
http://www.collplant.com
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the Company's expectations
regarding the timing and cost of commencing clinical trials with
respect to tissues and organs which are based on its rhCollagen
based BioInk, dermal fillers for aesthetics, VergenixSTR, and
VergenixFG; the Company's ability to obtain favorable pre-clinical
and clinical trial results; regulatory action with respect to
rhCollagen based BioInk, dermal fillers for aesthetics,
VergenixSTR, and VergenixFG including but not limited to acceptance
of an application for marketing authorization, review and approval
of such application, and, if approved, the scope of the approved
indication and labeling; commercial success and market acceptance
of the Company's rhCollagen based BioInk, dermal fillers for
aesthetics, VergenixSTR, and VergenixFG; the Company's ability to
establish sales and marketing capabilities or enter into agreements
with third parties and its reliance on third party distributors and
resellers; the Company's ability to establish and maintain
strategic partnerships and other corporate collaborations; the
Company's reliance on third parties to conduct some or all aspects
of its product manufacturing; the scope of protection the Company
is able to establish and maintain for intellectual property rights
and the Company's ability to operate its business without
infringing the intellectual property rights of others; the overall
global economic environment; the impact of competition and new
technologies; general market, political, and economic conditions in
the countries in which the Company operates; projected capital
expenditures and liquidity; changes in the Company's strategy; and
litigation and regulatory proceedings. More detailed information
about the risks and uncertainties affecting CollPlant is contained
under the heading "Risk Factors" included in CollPlant's most
recent annual report on Form 20-F filed with the SEC, and in other
filings that CollPlant has made and may make with the SEC in the
future. The forward-looking statements contained in this press
release are made as of the date of this press release and reflect
CollPlant's current views with respect to future events, and
CollPlant does not undertake and specifically disclaims any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact at
CollPlant:
|
|
|
|
Eran Rotem
|
|
Deputy CEO &
CFO
|
|
Tel: +
972-73-2325600
|
|
Email:
Eran@collplant.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/collplant-partners-in-the-advanced-regenerative-manufacturing-institute-300981447.html
SOURCE CollPlant